APUS (Apimeds) Market Valuation

The price action of Apimeds Pharmaceuticals (APUS) demonstrates the market position of a company that develops neuropreparations through partnerships with scientific centers to accelerate time-to-market. The current figure is 0.00. The business occupies a unique segment of apitherapy, which protects it from dumping despite competition with biotech behemoths. The strategy relies on the use of bee venom for the therapy of multiple sclerosis and arthritis.

APUS Apimeds Pharmaceuticals, Inc.: Market Capitalization in the range 05/10/2025 - 11/12/2026

Comprehensive metric breakdowns and analytics for apimedsus.com (APUS)

- market price and analyst price targets:

Price Chart Apimeds Pharmaceuticals US|APUS - Forecast Levels Chart

- business market valuation indicators:

Market Valuation Apimeds Pharmaceuticals, Inc.|APUS - Enterprise Value

- business book valuation details:

Net Assets per Single Share Apimeds Pharmaceuticals|APUS - Book Valuation of Business|Market Value to Book Value Ratio apimedsus.com|APUS - Total Asset Value of Company

- issuer credit burden and liquidity indicators:

Total Debt to Capital Apimeds Pharmaceuticals|APUS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Apimeds Pharmaceuticals US|APUS - Company Aggregate Debts|Debt to Book Capitalization Ratio Apimeds Pharmaceuticals, Inc.|APUS - Company Long-Term Loans and Borrowings|Company Short-Term Debt Apimeds Pharmaceuticals|Quick Ratio apimedsus.com

- business earnings and investment ratios data:

APUS - Net Profit|Future Profit Apimeds Pharmaceuticals|APUS - Company Value to Net Income|Future Price to Earnings Apimeds Pharmaceuticals US|APUS - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Apimeds Pharmaceuticals, Inc.|APUS - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Apimeds Pharmaceuticals|APUS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months apimedsus.com|APUS - Earnings per share increase in current year|Net earnings per share growth forecast for next year Apimeds Pharmaceuticals

Fundamental company analysis:APUS (Apimeds)

Apimeds Pharmaceuticals focuses on high-risk neurology developments based on bee venom. The total value of all shares shown on the company valuation chart filters out market noise to identify the real capitalization trend. This metric measures the aggregate market demand for the issuer's assets. Sharp fluctuations in the curve reflect the business's dependence on FDA verdicts. The indicator's dynamics determine the current cost of capital amid high uncertainty.

Key competitors